Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Therapies is Scopus-indexed (Q3, CiteScore 3.3), WoS SCIE. Published by Elsevier Masson s.r.l..
Checked against the index lists dated .
ISSN 0040-5957Verify ISSN ↗1958-5578Verify ISSN ↗
Publisher: Elsevier Masson s.r.l.
Cost to publish: About US$3,450 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 156 / 278 | 44th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1950–present (also 1947–1948), best quartile Q3, CiteScore 3.3.
Therapies is Q3 in Pharmacology (medical) (rank 156 of 278), by CiteScore 2025.
Therapies is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.3, which places it in quartile Q3 at the 44th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.557, quartile Q3, with an H-index of 46.
The publisher lists an article processing charge of about US$3,450 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Therapies is published by Elsevier Masson s.r.l. Its print ISSN is 0040-5957 and its online ISSN is 1958-5578.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Therapies has an h-index of 46 and a 2-year mean of 1.15 citations per paper (OpenAlex). Its Scopus CiteScore is 3.3, quartile Q3. On 2-year citations it ranks #175 of 271 Scopus journals in Pharmacology (medical).
Therapies published 93 papers in 2025; its busiest recent year was 2022 with 174. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2025–2026), authors are most often from France (88.5%), Tunisia (4.2%) and Switzerland (1.6%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.